Balyasny Asset Management’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-141,101
| Closed | -$20M | – | 3301 |
|
|
2025
Q4 | $20M | Sell |
141,101
-62,306
| -31% | -$9.03M | 0.03% | 716 |
|
|
2025
Q3 | $28.6M | Buy |
+203,407
| New | +$27.6M | 0.04% | 562 |
|
|
2025
Q2 | – | Sell |
-179,221
| Closed | -$19.8M | – | 3168 |
|
|
2025
Q1 | $19.8M | Sell |
179,221
-15,507
| -8% | -$1.96M | 0.03% | 599 |
|
|
2024
Q4 | $26.6M | Buy |
+194,728
| New | +$24.1M | 0.04% | 542 |
|
|
2024
Q2 | – | Sell |
-16,684
| Closed | -$2.3M | – | 2926 |
|
|
2024
Q1 | $2.3M | Sell |
16,684
-203,142
| -92% | -$27.7M | ﹤0.01% | 1504 |
|
|
2023
Q4 | $29M | Sell |
219,826
-258,262
| -54% | -$29.7M | 0.05% | 469 |
|
|
2023
Q3 | $53.8M | Sell |
478,088
-296,976
| -38% | -$31.3M | 0.11% | 245 |
|
|
2023
Q2 | $73.1M | Buy |
+775,064
| New | +$75.7M | 0.16% | 154 |
|
|
2022
Q1 | – | Sell |
-321,388
| Closed | -$27.4M | – | 2707 |
|
|
2021
Q4 | $27.4M | Buy |
321,388
+162,064
| +102% | +$14.9M | 0.09% | 293 |
|
|
2021
Q3 | $15.3M | Buy |
+159,324
| New | +$15M | 0.06% | 415 |
|
|
2020
Q3 | – | Sell |
-2,856
| Closed | -$348K | – | 1486 |
|
|
2020
Q2 | $348K | Buy |
+2,856
| New | +$316K | ﹤0.01% | 970 |
|
|
2019
Q4 | – | Sell |
-102,759
| Closed | -$9.26M | – | 1374 |
|
|
2019
Q3 | $9.26M | Buy |
+102,759
| New | +$9.6M | 0.06% | 416 |
|
|
2019
Q2 | – | Sell |
-99,366
| Closed | -$8.75M | – | 1645 |
|
|
2019
Q1 | $8.75M | Buy |
+99,366
| New | +$8.31M | 0.06% | 423 |
|
|
2018
Q4 | – | Sell |
-163,917
| Closed | -$20.2M | – | 1627 |
|
|
2018
Q3 | $20.2M | Sell |
163,917
-53,965
| -25% | -$6.12M | 0.09% | 302 |
|
|
2018
Q2 | $21.4M | Sell |
217,882
-15,934
| -7% | -$1.43M | 0.1% | 299 |
|
|
2018
Q1 | $19.4M | Sell |
233,816
-128,233
| -35% | -$10.8M | 0.08% | 339 |
|
|
2017
Q4 | $28.1M | Sell |
362,049
-240,633
| -40% | -$16.4M | 0.09% | 305 |
|
|
2017
Q3 | $36.9M | Buy |
+602,682
| New | +$31.8M | 0.14% | 192 |
|
|
2017
Q2 | – | Sell |
-13,856
| Closed | -$600K | – | 1640 |
|
|
2017
Q1 | $600K | Buy |
+13,856
| New | +$594K | ﹤0.01% | 1255 |
|
|
2016
Q4 | – | Sell |
-62,493
| Closed | -$3.17M | – | 1438 |
|
|
2016
Q3 | $3.17M | Buy |
+62,493
| New | +$3.11M | 0.02% | 571 |
|
|
2016
Q1 | – | Sell |
-96,250
| Closed | -$5.45M | – | 1438 |
|
|
2015
Q4 | $5.45M | Sell |
96,250
-109,047
| -53% | -$5.54M | 0.04% | 479 |
|
|
2015
Q3 | $8.17M | Buy |
205,297
+145,297
| +242% | +$7.02M | 0.06% | 398 |
|
|
2015
Q2 | $2.87M | Buy |
+60,000
| New | +$2.54M | 0.02% | 694 |
|
Other funds holding NBIX
VPM
VCM
Balyasny Asset Management's NBIX Position: Q1 2026 in Review
Balyasny Asset Management sold out of Neurocrine Biosciences (NBIX) in Q1 2026, closing a stake of 141,101 shares — an estimated $20M sold.
Balyasny Asset Management first reported a position in NBIX in Q2 2015 and held it in 23 quarters. The position peaked at $73.1M in Q2 2023. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.
- Balyasny Asset Management reported no remaining Neurocrine Biosciences position as of Q1 2026 after selling out during the quarter.
- Balyasny Asset Management sold 141,101 Neurocrine Biosciences shares in Q1 2026, an estimated $20M.
- Balyasny Asset Management first reported a position in Neurocrine Biosciences in Q2 2015 and held it in 23 quarters.
- Balyasny Asset Management's Neurocrine Biosciences position peaked at $73.1M in Q2 2023.
- 694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.
Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.